Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V. Hernández-Boluda JC, et al. Among authors: amat p. Blood. 2012 May 31;119(22):5221-8. doi: 10.1182/blood-2012-02-411215. Epub 2012 Apr 11. Blood. 2012. PMID: 22496165 Free article. Clinical Trial.
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Hernández-Boluda JC, et al. Among authors: amat p. Br J Haematol. 2011 Jan;152(1):81-8. doi: 10.1111/j.1365-2141.2010.08430.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083657 Free article.
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC. Guillem V, et al. Among authors: amat p. Leuk Res. 2012 Feb;36(2):174-81. doi: 10.1016/j.leukres.2011.06.011. Epub 2011 Jul 2. Leuk Res. 2012. PMID: 21724255
BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC. Guillem V, et al. Among authors: amat p. Leuk Res. 2015 Aug 28:S0145-2126(15)30367-2. doi: 10.1016/j.leukres.2015.08.014. Online ahead of print. Leuk Res. 2015. PMID: 26344465
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc. Marcé S, et al. Among authors: amat p. J Clin Med. 2021 Jul 16;10(14):3146. doi: 10.3390/jcm10143146. J Clin Med. 2021. PMID: 34300312 Free PMC article.
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L; Grupo Español de Leucemia Mieloide Crónica (GELMC). Marcé S, et al. Among authors: amat p. J Clin Med. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779. J Clin Med. 2024. PMID: 38337473 Free PMC article.
166 results